Key Highlights

  • Nuclea Energy has entered a definitive Business combination agreement with Mangoceuticals to obtain a Nasdaq listing.
  • Former Nuclea shareholders would hold approximately 96 percent of the combined company on a fully diluted basis.
  • The Morpheus microreactor is a lead-cooled, factory-built micro-modular reactor scalable from 3.5 MWe to 50 MWe.
  • Mangoceuticals has agreed to appoint at least three Nuclea-designated directors to its board at or following closing.

A Reverse merger Structure Aimed at Fast-Tracking a Nasdaq Listing

Nuclea Energy, an advanced nuclear technology company developing the Morpheus microreactor, announced it has entered into a definitive business combination agreement with Mangoceuticals (NASDAQ:MGRX), a men's health and wellness telemedicine company. Under the agreement, a newly formed indirect Subsidiary of Mangoceuticals will amalgamate with Nuclea, with the resulting company becoming an indirect Wholly Owned Subsidiary of Mangoceuticals.

Nuclea CEO Josef Freundorfer said the agreement gives the company a faster path to public markets at a defining moment for the nuclear industry, with Demand for continuous, carbon-free power accelerating as microreactors are built to serve data centers, defense installations, and remote sites the grid cannot efficiently reach. As a public company, Nuclea expects to gain Capital access and visibility to advance Morpheus toward first-of-a-kind delivery and execute its commercialization roadmap.

Former Nuclea Shareholders to Hold Approximately 96% of the Combined Entity

In connection with the amalgamation, holders of Nuclea common shares will receive exchangeable shares of a newly formed British Columbia subsidiary of Mangoceuticals, which will carry economic and voting rights intended to be substantially equivalent to Mangoceuticals common stock. Under the exchange ratio set out in the agreement, former Nuclea shareholders would hold approximately 96 percent of the combined company's fully diluted Equity immediately following closing, with Mangoceuticals' existing stockholders retaining approximately 4 percent.

Notably, closing of the transaction is expected to occur before Mangoceuticals stockholder approval and Nasdaq's approval of the initial listing application are obtained. Until those required approvals are secured, the economic, voting, and exchange rights attributable to the exchangeable shares will be capped at 19.99 percent of Mangoceuticals' outstanding common stock, with any rights beyond that threshold deferred rather than extinguished. Mangoceuticals has also agreed to appoint at least three Nuclea-designated directors to its board and to obtain voting support agreements from certain stockholders, while principal shareholders of both companies have agreed to customary lock-up arrangements.

Morpheus Microreactor Targets a Generational Shift in Electricity Demand

Morpheus is a lead-cooled, graphite-moderated microreactor currently in the conceptual design stage, scalable from approximately 3.5 MWe to 50 MWe of output, with inherent safety characteristics including a high boiling point lead coolant, near-atmospheric operating pressure, and passive natural-convection cooling that requires no pumps. The company has also developed a proprietary annular fuel configuration designed to extend refueling cycles to up to five years, well beyond the roughly 1.5 year industry standard, with the reactor designed to be factory-fabricated and transportable via standard rail and road shipping.

Nuclea is targeting applications across data centers, defense and military installations, remote Mining operations, and remote communities currently reliant on diesel generation, positioning the technology to benefit from growing hyperscaler and government interest in on-site and co-located power following two decades of largely flat US electricity consumption that is now projected to rise sharply due to AI infrastructure build-out and broader electrification trends.

Balancing Early-Stage Technology Risk Against Accelerating Power Demand Tailwinds

The transaction's success in providing Nuclea with meaningful capital market access will depend on securing the required Mangoceuticals stockholder approval, Nasdaq's non-objection to the exchangeable share structure, and various regulatory clearances including under the Investment Canada Act, the Competition Act, and the Hart-Scott-Rodino Antitrust Improvements Act. Should these approvals proceed smoothly, Nuclea would gain public market visibility at a moment when advanced nuclear technology is attracting substantial investor and government interest.

However, Morpheus remains in the conceptual design stage, meaning substantial technology development, nuclear licensing, and commercialization risk remains ahead of any actual reactor deployment. Mangoceuticals CEO Jacob Cohen acknowledged the scale of capital being committed to power the AI build-out, expressing confidence that advanced nuclear and microreactors will be a critical part of meeting that demand, though the ultimate realization of Morpheus's commercial potential will depend on execution across licensing, engineering, and Manufacturing milestones that extend well beyond the completion of this corporate transaction.

Conclusion

Nuclea Energy's business combination with Mangoceuticals reflects a growing trend of early-stage advanced nuclear developers seeking faster paths to public markets to Capitalize on accelerating electricity demand tied to AI infrastructure growth. Whether the transaction closes on its intended terms may depend on securing stockholder and Nasdaq approvals, while Morpheus's ultimate commercial success will hinge on progress through licensing and engineering milestones from its current conceptual design stage. The deal provides a clear illustration of how advanced nuclear technology companies are positioning themselves to benefit from the broader power demand tailwinds reshaping US energy infrastructure investment.